PP
AQST icon

Paloma Partners’s Aquestive Therapeutics AQST Stock Holding History

Paloma Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50,700
Closed -$213K – 1938
2019
Q2 		$213K Buy
+50,700
New +$260K ﹤0.01% 1510

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Paloma Partners's AQST Position: Q3 2019 in Review

Paloma Partners sold out of Aquestive Therapeutics (AQST) in Q3 2019, closing a stake of 50,700 shares — an estimated $213K sold.

Paloma Partners first reported a position in AQST in Q2 2019 and held it in 1 quarter. The position peaked at $213K in Q2 2019. 35 funds tracked by Wall St. Rank hold AQST as of Q3 2019.

  • Paloma Partners reported no remaining Aquestive Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 50,700 Aquestive Therapeutics shares in Q3 2019, an estimated $213K.
  • Paloma Partners first reported a position in Aquestive Therapeutics in Q2 2019 and held it in 1 quarter.
  • Paloma Partners's Aquestive Therapeutics position peaked at $213K in Q2 2019.
  • 35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.